Elanco Animal Health Incorporated
ELAN
Peringkat dalam Saham
#1871
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces,... Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Harga Saham
$22.70
Kapitalisasi Pasar
$11.34B
Perubahan (1 hari)
-3.45%
Perubahan (1 tahun)
4.49%
Negara
US
Perdagangan Elanco Animal Health Incorporated (ELAN)
Kategori
Healthcare
Laba untuk Elanco Animal Health Incorporated (ELAN)
Laba pada Jun 2026 TTM: $-166.00M
Menurut laporan keuangan terbaru dari Elanco Animal Health Incorporated, laba saat ini perusahaan adalah $-166.00M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-1.20B, penurunan dibandingkan dengan laba tahun 2022 sebesar $-72.00M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Elanco Animal Health Incorporated dari 2015 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-166.00M | -134.02% |
| 2024 | $488.00M | -140.84% |
| 2023 | $-1.20B | 1,559.72% |
| 2022 | $-72.00M | -87.39% |
| 2021 | $-571.00M | -15.03% |
| 2020 | $-672.00M | -959.34% |
| 2019 | $78.20M | -31.46% |
| 2018 | $114.10M | -149.05% |
| 2017 | $-232.60M | 938.39% |
| 2016 | $-22.40M | -91.37% |
| 2015 | $-259.50M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -1,162.98% |
IN
|
